Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

被引:4
|
作者
Hsu, Wei-Fan [1 ,2 ,3 ,9 ]
Chang, Kai-Chih [1 ]
Chen, Te-Hong [4 ,9 ]
Lin, Chien-Hung [5 ,9 ]
Lin, Ying-Chun [6 ,9 ]
Tsai, Ming-Hung [7 ,9 ]
Chen, Pei-Yu [8 ,9 ]
Wang, Hung-Wei [1 ,3 ,9 ]
Chu, Chia-Sheng [1 ,9 ]
Peng, Cheng-Yuan [1 ,3 ,9 ]
机构
[1] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, 2 Der Yuh Rd, Taichung 40447, Taiwan
[2] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan
[3] China Med Univ, Sch Med, Taichung, Taiwan
[4] China Med Univ Hosp, Dept Surg, Taichung, Taiwan
[5] China Med Univ Hosp, Dept Radiol, Taichung, Taiwan
[6] China Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan
[7] China Med Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Taichung, Taiwan
[8] China Med Univ Hosp, Dept Pathol, Taichung, Taiwan
[9] China Med Univ Hosp, Liver Canc Team, Taichung, Taiwan
关键词
albumin-bilirubin (ALBI) grade; intermediate-stage hepatocellular carcinoma; Lok grade; noninvasive model; SIGNIFICANT FIBROSIS; LIVER-FUNCTION; HEPATITIS-B; CIRRHOSIS; INDEX; ALBI; SUBCLASSIFICATION; CRITERIA; PROPOSAL; DISEASE;
D O I
10.1097/MD.0000000000027000
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models' OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55-72). Most patients had tumor volume <= 50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0-8.5) cm. The median alpha-fetoprotein was 36.25 (6.13-552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77-48.27) months. Across the 10 models, the albumin-bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595-0.693) in all patients. In subgroup analyses, the Lok index, platelet-albumin-bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Systemic chemotherapy for intermediate-stage hepatocellular carcinoma
    Ueshima, Kazuomi
    ANNALS OF ONCOLOGY, 2021, 32 : S269 - S269
  • [12] Liver Transplantation for Intermediate-Stage Hepatocellular Carcinoma
    Kamo, Naoko
    Kaido, Toshimi
    Yagi, Shintaro
    Okajima, Hideaki
    Uemoto, Shinji
    LIVER CANCER, 2018, 7 (02) : 179 - 189
  • [13] Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization
    Bannangkoon, Kittipitch
    Hongsakul, Keerati
    Tubtawee, Teeravut
    CANCER IMAGING, 2023, 23 (01)
  • [14] Post progression survival in patients with intermediate-stage hepatocellular carcinoma after receiving transarterial chemoembolization
    Shima, Yukiko
    Ogasawara, Sadahisa
    Ooka, Yoshihiko
    Kobayashi, Kazufumi
    Maruta, Susumu
    Kanzaki, Hiroaki
    Kanayama, Kengo
    Maeda, Takahiro
    Kusakabe, Yuko
    Kiyono, Soichiro
    Nakamura, Masato
    Saito, Tomoko
    Suzuki, Eiichiro
    Nakamoto, Shingo
    Yasui, Shin
    Tawada, Akinobu
    Chiba, Tetsuhiro
    Arai, Makoto
    Kanda, Tatsuo
    Maruyama, Hitoshi
    Kato, Naoya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E75 - E75
  • [15] OVERALL SURVIVAL IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS AFTER FIRST TRANSARTERIAL CHEMOEMBOLIZATION (TACE): PROPOSAL OF A NEW SCORING SYSTEM
    Sacco, R.
    Ginanni, B.
    Mismas, V.
    Masi, G.
    De Simone, P.
    Romano, A.
    Bresci, G.
    Bartolozzi, C.
    Bargellini, I.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E44 - E44
  • [16] OVERALL SURVIVAL IN INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC) PATIENTS AFTER FIRST TRANSARTERIAL CHEMOEMBOLIZATION (TACE): PROPOSAL OF A NEW SCORING SYSTEM
    Sacco, R.
    Ginanni, B.
    Masi, G.
    De Simone, P.
    Bresci, G.
    Bartolozzi, C.
    Bargellini, I.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E183 - E184
  • [17] Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
    Zhuang, Lei
    Wen, Tianfu
    Xu, Mingqing
    Yang, Jiayin
    Wang, Wentao
    Wu, Hong
    Yan, Lvnan
    Wei, Yonggang
    Li, Bo
    HEPATOLOGY, 2014, 60 : 886A - 886A
  • [18] Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
    Zhuang, Lei
    Wen, Tianfu
    Xu, Mingqing
    Yang, Jiayin
    Wang, Wentao
    Wu, Hong
    Zeng, Yong
    Yan, Lvnan
    Wei, Yonggang
    Li, Bo
    ARCHIVES OF MEDICAL SCIENCE, 2017, 13 (06) : 1383 - 1393
  • [19] A Retrospective Study on Predicting Recurrence of Intermediate-Stage Hepatocellular Carcinoma After Radical Therapy
    Han, Ruyu
    Gan, Leijuan
    Lang, Mengran
    Li, Guangtao
    Chen, Lu
    Tian, Xindi
    Zhu, Kangwei
    Sun, Liyu
    Song, Tianqiang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 51 - 64
  • [20] Overall survival in intermediate-stage hepatocellular carcinoma (HCC) patients after first transarterial chemoembolization (TACE): Proposal of a new scoring system.
    Sacco, Rodolfo
    Mismas, Valeria
    Romano, Antonio
    Ginanni, Barbara
    Marceglia, Sara
    Giacomelli, Luca
    Masi, Gianluca
    Falcone, Alfredo
    Bresci, Giampaolo
    Bartolozzi, Carlo
    Bargellini, Irene
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)